TY - JOUR
T1 - Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
AU - Petta, Salvatore
AU - Aghemo, Alessio
AU - Xing, Chao
AU - Donati, Benedetta
AU - Pietrelli, Alessandro
AU - Pelusi, Serena
AU - Grieco, Antonio
AU - Meroni, Marica
AU - Baselli, Guido
AU - Mccain, Misti Vanette
AU - Soardo, Giorgio
AU - D’Ambrosio, Roberta
AU - Romeo, Stefano
AU - De Francesco, Raffaele
AU - Valenti, Luca Vittorio Carlo
AU - Dongiovanni, Paola
AU - Bugianesi, Elisabetta
AU - Fracanzani, Anna Ludovica
AU - De Francesco, Raffaele
AU - Valenti, Luca Vittorio Carlo
AU - Reeves, Helen Louise
AU - Miele, Luca
AU - Fargion, Silvia
AU - Romagnoli, Renato
PY - 2019
Y1 - 2019
N2 - Nonalcoholic fatty liver disease (NAFLD) is a rising cause of hepatocellular carcinoma (HCC). We examined whether inherited pathogenic variants in candidate genes (n = 181) were enriched in patients with NAFLD-HCC. To this end, we resequenced peripheral blood DNA of 142 NAFLD-HCC, 59 NAFLD with advanced fibrosis, and 50 controls, and considered 404 healthy individuals from 1000 G. Pathogenic variants were defined according to ClinVar, likely pathogenic as rare variants predicted to alter protein activity. In NAFLD-HCC patients, we detected an enrichment in pathogenic (p = 0.024), and likely pathogenic variants (p = 1.9*10-6), particularly in APOB (p = 0.047). APOB variants were associated with lower circulating triglycerides and higher HDL cholesterol (p < 0.01). A genetic risk score predicted NAFLD-HCC (OR 4.96, 3.29-7.55; p = 5.1*10-16), outperforming the diagnostic accuracy of common genetic risk variants, and of clinical risk factors (p < 0.05). In conclusion, rare pathogenic variants in genes involved in liver disease and cancer predisposition are associated with NAFLD-HCC development.
AB - Nonalcoholic fatty liver disease (NAFLD) is a rising cause of hepatocellular carcinoma (HCC). We examined whether inherited pathogenic variants in candidate genes (n = 181) were enriched in patients with NAFLD-HCC. To this end, we resequenced peripheral blood DNA of 142 NAFLD-HCC, 59 NAFLD with advanced fibrosis, and 50 controls, and considered 404 healthy individuals from 1000 G. Pathogenic variants were defined according to ClinVar, likely pathogenic as rare variants predicted to alter protein activity. In NAFLD-HCC patients, we detected an enrichment in pathogenic (p = 0.024), and likely pathogenic variants (p = 1.9*10-6), particularly in APOB (p = 0.047). APOB variants were associated with lower circulating triglycerides and higher HDL cholesterol (p < 0.01). A genetic risk score predicted NAFLD-HCC (OR 4.96, 3.29-7.55; p = 5.1*10-16), outperforming the diagnostic accuracy of common genetic risk variants, and of clinical risk factors (p < 0.05). In conclusion, rare pathogenic variants in genes involved in liver disease and cancer predisposition are associated with NAFLD-HCC development.
UR - http://hdl.handle.net/10447/345485
M3 - Article
SN - 2045-2322
VL - 9
SP - 3682-
JO - Scientific Reports
JF - Scientific Reports
ER -